{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:49:57Z","timestamp":1794437397912,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":77,"publisher":"Springer New York","isbn-type":[{"value":"9781461446590","type":"print"},{"value":"9781461446606","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T00:00:00Z","timestamp":1353628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T00:00:00Z","timestamp":1353628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-1-4614-4660-6_1","type":"book-chapter","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T04:44:38Z","timestamp":1357620278000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetics of Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Steven","family":"Schuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,23]]},"reference":[{"key":"1_CR00011","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0165-4608(97)00058-7","volume":"101","author":"GJ Ahmann","year":"1998","unstructured":"Ahmann GJ, Jalal SM, Juneau AL et al (1998) A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogene 101:7\u201311","journal-title":"Cancer Genet Cytogene"},{"key":"1_CR00012","first-page":"4546","volume":"59","author":"H Avet-Loiseau","year":"1999","unstructured":"Avet-Loiseau H, Facon T, Daviet A et al (1999a) 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome Cancer Res 59:4546\u20134550","journal-title":"Intergroupe Francophone du Myelome. Cancer Res"},{"key":"1_CR00013","first-page":"2583","volume":"94","author":"H Avet-Loiseau","year":"1999","unstructured":"Avet-Loiseau H, Li JY, Morineau N et al (1999b) Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome Blood 94:2583\u20132589","journal-title":"Intergroupe Francophone du Myelome. Blood"},{"key":"1_CR00014","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2002-08-2436","volume":"101","author":"H Avet-Loiseau","year":"2003","unstructured":"Avet-Loiseau H, Garand R, Lod\u00e9 L et al (2003) Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 101:1570\u20131571","journal-title":"Blood"},{"key":"1_CR00015","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P et al (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myelome. Blood 109:3489\u20133495","journal-title":"Blood"},{"key":"1_CR00016","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","volume":"27","author":"H Avet-Loiseau","year":"2009","unstructured":"Avet-Loiseau H, Li C, Magrangeas F et al (2009) Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585\u20134590","journal-title":"J Clin Oncol"},{"key":"1_CR00017","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Leleu X, Roussel M et al (2010a) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630\u20134634","journal-title":"J Clin Oncol"},{"key":"1_CR00018","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/leu.2009.273","volume":"24","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Soulier J, Fermand JP et al (2010b) Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 24:623\u2013628","journal-title":"Leukemia"},{"key":"1_CR00019","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","volume":"117","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Malard F, Campion L et al (2010c) Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 117:2009\u20132011","journal-title":"Blood"},{"key":"1_CR000110","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1034\/j.1600-065X.2003.00052.x","volume":"194","author":"PL Bergsagel","year":"2003","unstructured":"Bergsagel PL, Kuehl WM (2003) Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96\u2013104","journal-title":"Immunol Rev"},{"key":"1_CR000111","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 106:296\u2013303","journal-title":"Blood"},{"key":"1_CR000112","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.seminhematol.2010.11.007","volume":"48","author":"KR Calvo","year":"2011","unstructured":"Calvo KR, Landgren O, Roccaro AM et al (2011) Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Seminars Hematolo 48:39\u201345","journal-title":"Seminars Hematolo"},{"key":"1_CR000113","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","volume":"9","author":"DR Carrasco","year":"2006","unstructured":"Carrasco DR, Tonon G, Huang Y et al (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313\u2013325","journal-title":"Cancer Cell"},{"key":"1_CR000114","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/sj.bmt.1705131","volume":"36","author":"H Chang","year":"2005","unstructured":"Chang H, Qi XY, Samiee S et al (2005a) Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 36:793\u2013796","journal-title":"Bone Marrow Transplant"},{"key":"1_CR000115","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","volume":"105","author":"H Chang","year":"2005","unstructured":"Chang H, Qi C, Yi QL et al (2005b) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105:358\u2013360","journal-title":"Blood"},{"key":"1_CR000116","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2141.2007.06750.x","volume":"139","author":"H Chang","year":"2007","unstructured":"Chang H, Ning Y, Qi X et al (2007) Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 139:51\u201354","journal-title":"Br J Haematol"},{"key":"1_CR000117","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.leukres.2008.06.027","volume":"33","author":"H Chang","year":"2009","unstructured":"Chang H, Qi X, Yeung J et al (2009) Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leukemia Res 33:259\u2013262","journal-title":"Leukemia Res"},{"key":"1_CR000118","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/bmt.2009.107","volume":"45","author":"H Chang","year":"2010","unstructured":"Chang H, Qi X, Jiang A et al (2010a) 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 45:117\u2013121","journal-title":"Bone Marrow Transplant"},{"key":"1_CR000119","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3324\/haematol.2010.022210","volume":"95","author":"H Chang","year":"2010","unstructured":"Chang H, Jiang N, Jiang H et al (2010b) CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in multiple myeloma. Haematologica 95:1542\u20131547","journal-title":"Haematologica"},{"key":"1_CR000120","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471:467\u2013472","journal-title":"Nature"},{"key":"1_CR000121","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","volume":"94","author":"L Chiecchio","year":"2009","unstructured":"Chiecchio L, Dagrada GP, Ibrahim AH et al (2009) Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 94:1708\u20131713","journal-title":"Haematologica"},{"key":"1_CR000122","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","volume":"21","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Price-Troska T, Gonzalez-Paz N et al (2007) Clinical significance of TP53 mutation in myeloma. Leukemia 21:582\u2013584","journal-title":"Leukemia"},{"key":"1_CR000123","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood-2007-06-097774","volume":"111","author":"WJ Chng","year":"2008","unstructured":"Chng WJ, Braggio E, Mulligan G et al (2008) The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 111:1603\u20131609","journal-title":"Blood"},{"key":"1_CR000124","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino A et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Scit USA 102:13944\u201313949 [Erratum appears in Proc Natl Acad Sci USA 2006 Feb 14;103(7):2464]","journal-title":"Proc Natl Acad Scit U S A"},{"key":"1_CR000125","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj.leu.2402797","volume":"17","author":"C Debes-Marun","year":"2003","unstructured":"Debes-Marun C, Dewald GW, Bryant S et al (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17:427\u2013436","journal-title":"Leukemia"},{"key":"1_CR000126","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux O, Lod\u00e9 L, Magrangeas F et al (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Onco 26:4798\u20134805","journal-title":"J Clin Onco"},{"key":"1_CR000127","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V66.2.380.380","volume":"66","author":"GW Dewald","year":"1985","unstructured":"Dewald GW, Kyle RA, Hicks GA et al (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380\u2013390","journal-title":"Blood"},{"key":"1_CR000128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","volume":"82","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Rajkumar SV, Gertz MA et al (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 82:323\u2013341","journal-title":"Mayo Clin Proc"},{"key":"1_CR000129","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","volume":"92","author":"J Drach","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E et al (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92:802\u2013809","journal-title":"Blood"},{"issue":"3","key":"1_CR000130","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842\u2013854","journal-title":"Cancer"},{"key":"1_CR000131","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/asheducation-2007.1.304","volume":"2","author":"R Fonseca","year":"2007","unstructured":"Fonseca R (2007) Strategies for risk-adapted therapy in myeloma. Hematol Am Soc Hematol Educ Program 2:304\u2013310","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1_CR000132","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.hoc.2007.08.010","volume":"21","author":"R Fonseca","year":"2007","unstructured":"Fonseca R, San Miguel J (2007) Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 21:1115\u20131140","journal-title":"Hematol Oncol Clin North Am"},{"key":"1_CR000133","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","volume":"100","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Bailey RJ, Ahmann GJ et al (2002) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100:1417\u20131424","journal-title":"Blood"},{"key":"1_CR000134","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","volume":"102","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Debes-Marun CS, Picken EB et al (2003a) The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562\u20132567","journal-title":"Blood"},{"key":"1_CR000135","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M et al (2003b) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569\u20134575","journal-title":"Blood"},{"key":"1_CR000136","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","volume":"64","author":"R Fonseca","year":"2004","unstructured":"Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546\u20131558","journal-title":"Cancer Res"},{"key":"1_CR000137","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J et al (2009) International myeloma working group molecular classification of multiple myeloma: Spotlight review. Leukemia 23:2210\u20132221","journal-title":"Leukemia"},{"key":"1_CR000138","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/sj.leu.2403091","volume":"17","author":"R Garand","year":"2003","unstructured":"Garand R, Avet-Loiseau H, Accard F et al (2003) t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 17:2032\u20132035","journal-title":"Leukemia"},{"key":"1_CR000140","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","volume":"106","author":"MA Gertz","year":"2005","unstructured":"Gertz MA et al (2005) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106:2837\u20132840","journal-title":"Blood"},{"key":"1_CR000141","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"1_CR000142","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"NC Gutierrez","year":"2007","unstructured":"Gutierrez NC, Castellanos MV, Mart\u00edn ML et al (2007) Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21:143\u2013150","journal-title":"Leukemia"},{"key":"1_CR000143","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.leu.2404442","volume":"21","author":"S Jagannath","year":"2007","unstructured":"Jagannath S, Richardson PG, Sonneveld P et al (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151\u2013157","journal-title":"Leukemia"},{"key":"1_CR000144","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","volume":"114","author":"P Kapoor","year":"2009","unstructured":"Kapoor P, Kumar S, Fonseca R et al (2009) Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114:518\u2013521","journal-title":"Blood"},{"key":"1_CR000145","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4065\/mcp.2009.0677","volume":"85","author":"P Kapoor","year":"2010","unstructured":"Kapoor P, Fonseca R, Rajkumar SV et al (2010) Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel \u00adtherapy. Mayo Clin Proc 85:532\u2013537","journal-title":"Mayo Clin Proc"},{"key":"1_CR000146","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M et al (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12:131\u2013144","journal-title":"Cancer Cell"},{"key":"1_CR000147","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","volume":"84","author":"SK Kumar","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84:1095\u20131110","journal-title":"Mayo Clin Proc"},{"key":"1_CR000148","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Fonseca R, Ketterling RP et al (2012) Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119:2100\u20132105","journal-title":"Blood"},{"key":"1_CR000149","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/B978-0-12-386469-7.00002-5","volume":"110","author":"M Lemaire","year":"2011","unstructured":"Lemaire M, Deleu S, De Bruyne E et al (2011) The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res 110:19\u201342","journal-title":"Adv Cancer Res"},{"key":"1_CR000150","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1182\/blood-2009-08-237495","volume":"114","author":"M Lionetti","year":"2009","unstructured":"Lionetti M, Landgren O, Roccaro AM et al (2009) Identification of microRNA expression patterns and definition of a microRNA\/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114:e20\u201326","journal-title":"Blood"},{"key":"1_CR000151","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","volume":"88","author":"P Liu","year":"1996","unstructured":"Liu P, Leong T, Quam L et al (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the eastern cooperative oncology group phase III trial. Blood 88:2699\u20132706","journal-title":"Blood"},{"key":"1_CR000152","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood-2007-03-081133","volume":"110","author":"D Loffler","year":"2007","unstructured":"Loffler D, Brocke-Heidrich K, Pfeifer G et al (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110:1330\u20131333","journal-title":"Blood"},{"issue":"7","key":"1_CR000153","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","volume":"17","author":"L Lopez-Corral","year":"2011","unstructured":"Lopez-Corral L, Guti\u00e9rrez NC, Vidriales MB et al (2011) The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clini Cancer Res 17(7):1692\u20131700","journal-title":"Clini Cancer Res"},{"key":"1_CR000154","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V116.21.309.309","volume":"116","author":"M Mateos","year":"2010","unstructured":"Mateos M, Guitterez NC, Paiva B et al (2010) Clinical outcome according to both cytogenetic abnormalities (CA) detected by Fluorescence In Situ Hybridization (FISH) and hyperdiploidy assessed by Flow Cytometry (FCM) in elderly newly diagnosed myeloma patients treated with a bortezomib-based combination. Blood November 2010; 116: 309.","journal-title":"Blood November"},{"key":"1_CR000155","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","volume":"17","author":"NC Munshi","year":"2011","unstructured":"Munshi NC, Avet-Loiseau H (2011) Genomics in multiple myeloma. Clin Cancer Res 17:1234\u20131242","journal-title":"Clin Cancer Res"},{"key":"1_CR000156","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair B, van Rhee F, Shaughnessy JD Jr et al (2010) Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance. Blood 115:4168\u20134173","journal-title":"Blood"},{"key":"1_CR000157","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","volume":"81","author":"A Neri","year":"1993","unstructured":"Neri A, Baldini L, Trecca D et al (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128\u2013135","journal-title":"Blood"},{"key":"1_CR000158","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/nature09658","volume":"470","author":"H Pei","year":"2011","unstructured":"Pei H, Zhang L, Luo K et al (2011) MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470:124\u2013128","journal-title":"Nature"},{"key":"1_CR000159","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1073\/pnas.0806202105","volume":"105","author":"F Pichiorri","year":"2008","unstructured":"Pichiorri F, S-s S, Ladetto M et al (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105:12885\u201312890","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR000160","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","volume":"114","author":"D Reece","year":"2009","unstructured":"Reece D, Song KW, Fu T et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114:522\u2013525","journal-title":"Blood"},{"key":"1_CR000161","first-page":"4","volume":"4","author":"P Richardson","year":"2006","unstructured":"Richardson P (2006) Optimizing bortezomib treatment in patients with relapsed multiple myeloma. Clin Adv Hematol Oncol 4:4\u20135; discussion 8; suppl 13","journal-title":"Clin Adv Hematol Oncol"},{"key":"1_CR000162","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.leu.2403857","volume":"19","author":"FM Ross","year":"2005","unstructured":"Ross FM, Ibrahim AH, Vilain-Holmes A et al (2005) Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19:1634\u20131642","journal-title":"Leukemia"},{"key":"1_CR000163","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","volume":"95","author":"FM Ross","year":"2010","unstructured":"Ross FM, Chiecchio L, Dagrada GP et al (2010) The t(14;20) is a poor prognostic factor in myeloma but is associated with long term stable disease in MGUS. Haematologica 95:1221\u20131225","journal-title":"Haematologica"},{"key":"1_CR000164","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"1_CR000165","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood.V100.8.2996","volume":"100","author":"RF Schop","year":"2002","unstructured":"Schop RF, Kuehl WM, Van Wier SA et al (2002) Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 100:2996\u20133001","journal-title":"Blood"},{"key":"1_CR000166","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ajh.21845","volume":"85","author":"SR Schuster","year":"2010","unstructured":"Schuster SR, Rajkumar SV, Dispenzieri A et al (2010) IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom\u2019s macroglobulinemia. Am J Hematol 85:853\u2013855","journal-title":"Am J Hematol"},{"key":"1_CR000167","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/wsbm.89","volume":"2","author":"A Sharma","year":"2010","unstructured":"Sharma A, Heuck CJ, Fazzari MJ et al (2010) DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdisciplinary Rev Syst Biol Med 2:654\u2013669","journal-title":"Wiley Interdisciplinary Rev. Syst Biol Med"},{"key":"1_CR000168","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE et al (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276\u20132284","journal-title":"Blood"},{"key":"1_CR000169","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/sj.leu.2401041","volume":"12","author":"NV Smadja","year":"1998","unstructured":"Smadja NV, Fruchart C, Isnard F et al (1998) Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12:960\u2013969","journal-title":"Leukemia"},{"key":"1_CR000170","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2141.2009.07976.x","volume":"148","author":"EM Smith","year":"2009","unstructured":"Smith EM, Boyd K, Davies FE (2009) The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 148:702\u2013713","journal-title":"Br J Haematol"},{"key":"1_CR000171","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","volume":"22","author":"RE Tiedemann","year":"2008","unstructured":"Tiedemann RE, Gonzalez-Paz N, Kyle RA et al (2008) Genetic aberrations and survival in plasma cell leukemia. Leukemia 22:1044\u20131052","journal-title":"Leukemia"},{"key":"1_CR000172","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3324\/haematol.2009.012088","volume":"95","author":"K Todoerti","year":"2010","unstructured":"Todoerti K, Barbui V, Pedrini O et al (2010) Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 95:260\u2013269","journal-title":"Haematologica"},{"key":"1_CR000173","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","volume":"86","author":"G Tricot","year":"1995","unstructured":"Tricot G, Barlogie B, Jagannath S et al (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250\u20134256","journal-title":"Blood"},{"key":"1_CR000174","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1997.15.7.2659","volume":"15","author":"G Tricot","year":"1997","unstructured":"Tricot G, Sawyer JR, Jagannath S et al (1997) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659\u20132666","journal-title":"J Clin Oncol"},{"key":"1_CR000175","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","volume":"112","author":"W Xiong","year":"2008","unstructured":"Xiong W, Wu X, Starnes S et al (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112:4235\u20134246","journal-title":"Blood"},{"key":"1_CR000176","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020\u20132028","journal-title":"Blood"},{"key":"1_CR000177","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Colla S, Wu X et al (2007) CKS1B, over expressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and independent mechanisms. Blood 109:4995\u20135001","journal-title":"Blood"},{"key":"1_CR000178","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX et al (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771\u20134779","journal-title":"Blood"}],"container-title":["Genetic and Molecular Epidemiology of Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-4660-6_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T01:27:31Z","timestamp":1674178051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-4614-4660-6_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,23]]},"ISBN":["9781461446590","9781461446606"],"references-count":77,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-4660-6_1","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4614-4660-6","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2012,11,23]]},"assertion":[{"value":"23 November 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}